Please use this identifier to cite or link to this item:
|Title:||Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells|
|Authors:||Mach, François;Sauty, Alain;Iarossi, Albert S.;Sukhova, Galina K.;Neote, Kuldeep;Libby, Peter;Luster, Andrew David|
|Publisher:||American Society for Clinical Investigation|
|Description:||Activated T lymphocytes accumulate early in atheroma formation and persist at sites of lesion growth and rupture, suggesting that they may play an important role in the pathogenesis of atherosclerosis. Moreover, atherosclerotic lesions contain the Th1-type cytokine IFN-gamma, a potentiator of atherosclerosis. The present study demonstrates the differential expression of the 3 IFN-gamma-inducible CXC chemokines--IFN-inducible protein 10 (IP-10), monokine induced by IFN-gamma (Mig), and IFN-inducible T-cell alpha chemoattractant (I-TAC)--by atheroma-associated cells, as well as the expression of their receptor, CXCR3, by all T lymphocytes within human atherosclerotic lesions in situ. Atheroma-associated endothelial cells (ECs), smooth muscle cells (SMCs), and macrophages (MO) all expressed IP-10, whereas Mig and I-TAC were mainly expressed in ECs and MO, as detected by double immunofluorescence staining. ECs of microvessels within lesions also expressed abundant I-TAC. In vitro experiments supported these results and showed that IL-1beta, TNF-alpha, and CD40 ligand potentiated IP-10 expression from IFN-gamma-stimulated ECs. In addition, nitric oxide (NO) treatment decreased IFN-gamma induction of IP-10. Our findings suggest that the differential expression of IP-10, Mig, and I-TAC by atheroma-associated cells plays a role in the recruitment and retention of activated T lymphocytes observed within vascular wall lesions during atherogenesis.|
|Standard no:||Mach, François, Alain Sauty, Albert S. Iarossi, Galina K. Sukhova, Kuldeep Neote, Peter Libby, and Andrew D. Luster. 1999. “Differential Expression of Three T Lymphocyte-Activating CXC Chemokines by Human Atheroma-Associated Cells.” J. Clin. Invest. 104 (8) (October 15): 1041–1050. doi:10.1172/jci6993.|
|Appears in Collections:||HMS Scholarly Articles|
Files in This Item:
Click on the URI links for accessing contents.
Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.